eMedicine Specialties > Otolaryngology and Facial Plastic Surgery > Head & Neck Surgery

Malignant Tumors of the Larynx

Author: Jonas T Johnson, MD, FACS, Chairman, Department of Otolaryngology, The Eugene N Myers, MD, Professor and Chairman of Otolaryngology, Professor, Department of Radiation Oncology, University of Pittsburgh School of Medicine; Professor, Department of Oral Maxillofacial Surgery, University of Pittsburgh School of Dental Medicine
Coauthor(s): Apostolos Christopoulos, MD, MSc, FRCSC, Fellow in Head and Neck Oncologic Surgery, Department of Otolaryngology, University of Pittsburgh; Emiro E Caicedo-Granados, MD, Fellow in Head and Neck Oncology/Anterior Endoscopic Skull Base Surgery, Department of Otolaryngology, University of Pittsburgh
Contributor Information and Disclosures

Updated: Jan 7, 2009

Introduction

Malignancies of the upper aero-digestive tract are a leading cause of death in the United States of America. Among all the cancers of the upper aero-digestive tract, squamous cell carcinoma is the most common. Approximately 40,000 new patients are diagnosed with squamous cell carcinoma of the head and neck each year in the United States. An estimated 12,500 men and women in the United States will be diagnosed with laryngeal squamous cell carcinoma in 2008.

Treatment of laryngeal carcinoma has changed during the last years. At the beginning of the century, therapies were surgically directed. Total and partial laryngectomy surgeries were and still are the mainstream surgical procedures to treat malignant tumors of the larynx. A paradigm change in treatment was experienced in the early 1990s. The organ preservation treatments using concurrent chemoradiation therapy were introduced. This treatment approach demonstrated survival rates similar to total laryngectomy plus radiation therapy, while preserving the larynx in 63% of the patients. In addition, new developments in endoscopic surgical techniques and laser equipment are opening a new era in the treatment of malignant tumor of the larynx.

History Of The Procedure

The development of the technique of direct laryngoscopy by Manuel Garcia in 1855 provided the ability to examine the larynx in a living person for the first time. The first laryngofissure procedure for cancer was performed by Gurdon Buck in 1851, while Theodor Billroth is credited with the first laryngectomy in 1873. Postoperative mortality from this procedure was very high (around 40%), mainly due to aspiration and sepsis.

Constant improvement in technique and perioperative care led to improved outcomes. A standardized laryngectomy technique perfected by Gluck and Soerensen by 1922 yielded excellent surgical outcomes with few fatalities. Billroth and Gluck also described hemilaryngectomies, but these procedures resulted in high recurrence rates and intractable dysphagia. Partial laryngectomies gradually regained an important role as a therapeutic option for laryngeal cancer mainly through improved techniques and recognition of appropriate indications. In recent years, surgery of laryngeal cancer has evolved to refined endoscopic and laser techniques.

Problem

New strategies using chemotherapy, radiotherapy and surgery have not substantially changed the survival rate of patients with advanced malignant tumors of the larynx in the last 30 years. Tobacco and alcohol are recognized as the major risk factors for developing malignant tumors of the larynx. New efforts in understanding the molecular biology and carcinogenesis of laryngeal malignancies have given us knowledge in the evolution of this disease and have shown therapeutic potential. The main challenge in laryngeal cancer treatment is improving survival while preserving function by limiting treatment toxicities.

Frequency

According to the SEER Cancer Statistics Review of the National Cancer Institute, an estimated 12,250 men and women will be diagnosed with cancer of the larynx in 2008; of those, 3,670 patients will die. The age-adjusted incidence is 3.6 per 100,000 with a mortality of 1.3 per 100,000.

Etiology

Until the complex molecular interactions of all associated etiologic agents for any cancer can be understood, these interactions are best thought of as associations. Thinking of intrinsic (eg, genetic) factors and/or extrinsic (eg, smoking) factors as causes is too simple.

To most people, a cause implies a condition that is both necessary and sufficient to produce a prespecified result. Laryngeal carcinomas have multiple associations.

The foremost risk factor for the development of laryngeal cancer is tobacco use. The risk of developing laryngeal cancer with tobacco increases with use and decreases after cessation. When associated with the intake of alcohol, a strong synergistic effect is created. However, whether or not alcohol alone is an independent risk factor is still unclear.

All the potential risk factors for laryngeal cancer that have been studied are as follows:

  • Tobacco use
  • Excessive ethanol use
  • Male sex
  • Infection with human papillomavirus
  • Increasing age
  • Diets low in green leafy vegetables
  • Diets rich in salt preserved meats and dietary fats 
  • Metal/plastic workers
  • Exposure to paint
  • Exposure to diesel and gasoline fumes
  • Exposure to asbestos
  • Exposure to radiation
  • Laryngopharyngeal reflux

Pathophysiology

The larynx is an essential organ that is responsible for the following vital functions:

  • Maintaining an open air way
  • Vocalizing
  • Protecting the lungs from more direct exposure to noxious fumes and gases of unsuitable temperatures
  • Protecting the lungs from aspiration of solids and liquids
  • Allowing leverage, by closing the glottis during a Valsalva maneuver, to increase upper-body strength and to ease solid-waste removal

Malignant tumors of the larynx affect laryngeal physiology depending on tumor location and size. Supraglottic tumors usually cause upper airway obstruction. Conversely, glottic tumors affect initially voice quality. In addition, malignant tumors of the larynx affect swallowing physiology. The mechanism of swallowing is altered when tumors invade and alter the physiology of the swallowing muscles. This is expressed as difficulty swallowing and aspiration. Liquids and solid food gain access into the trachea.

Pathophysiology of malignant tumors of the larynx is at the molecular and histologic level. Histologic progression occurs from normal laryngeal mucosa to dysplastic mucosa to carcinoma in situ to invasive carcinoma. This progression is a multistep process of accumulated genetic events that lead to the development of larynx tumors.

Presentation

Given the functions of the larynx mentioned above, one can easily imagine the consequences of a carcinoma destroying and/or obstructing the laryngeal structures and their mechanisms (eg, vocal-cord movement). Symptoms vary with the structures involved by malignancy and its accompanying inflammatory reaction. Although the particular tumor, the site, and the patient's constitution play key roles in any given individual, laryngeal cancers as a whole can cause any of the following findings, alone or in combination:

  • Dysphonia/aphonia
  • Dysphagia
  • Dyspnea
  • Aspiration
  • Blood-tinged sputum
  • Fatigue and weakness
  • Cachexia
  • Pain
  • Halitosis
  • Actual expectoration of tissue
  • Neck mass
  • Otalgia (Outside the field of otorhinolaryngology, many physicians do not realize that otalgia may be a sign of laryngeal cancer. This seems to be especially true if the arytenoids are involved.)

History

As in all clinical evaluations, the history is the first step in gathering the facts. Assess or inquire about the following:

  • Weight loss
  • Fatigue
  • Pain
  • Difficulty breathing or swallowing
  • Vocal changes noted by the patient and his or her family
  • Ear pain
  • Coughing up blood or solid material

Physical examination

The patient's general condition and nutritional status should be evaluated. A full head and neck examination should be completed. Head and neck examination includes inspection and palpation of the oral cavity and oropharynx to rule out second primary tumors or other lesions, as well as evaluation of dentition. Inspection of the larynx is best accomplished using a flexible laryngoscope. Flexible laryngoscopy allows the otolaryngologist to evaluate the function and anatomy of the entire larynx. Evaluation of vocal cord motility and the location and extension of the tumor are crucial to stage the patient accurately.

Palpation of the neck looking for enlarged lymph nodes is paramount in the patient's evaluation. Thorough evaluation of the cranial nerves should also be included in the physical examination.

Indications

Many laryngeal tumors may appear late with distant metastasis and near-total destruction of some neck structures. Others may appear early. Treatment is necessary for all tumors. Although supplying comfort may be only palliative, it should still be addressed because tumors of the larynx can cause severe misery for the patient and his or her loved ones.

Treatment may include single therapy or combinations of surgery, radiation therapy, and/or chemotherapy. To select proper therapy, all of the necessary information must first be obtained before available options are discussed with the patient. The anatomy of the larynx is complex and difficult to visualize. Nevertheless, the team caring for each patient must understand it. Specialists in the areas of surgery, pathology, radiation oncology, and radiology understand this anatomy well. For family members, patients, and clinicians who do not deal with anatomic detail in their daily practice, this is a complicated arena. The entire team must effectively understand each other and communicate with the family.

Relevant Anatomy

Entire books are written about gross and microscopic laryngeal anatomy. The discussion below is an abbreviated version of the relevant anatomy. It should provide the information any clinician needs to understand this anatomic region, and it should explain why different procedures are indicated in different areas. It also helps in clarifying the consequences of each procedure.  

Based on anatomic location, the larynx is divided into the supraglottic larynx, the glottis or glottic larynx, and the subglottic larynx. The supraglottic larynx includes the epiglottis, the preepiglottic space, the laryngeal aspects of the aryepiglottic folds, the false vocal cords, the arytenoids, and the ventricles. The inferior boundary is a horizontal plane drawn trough the apex of the ventricle. This corresponds to the area of transition from squamous to respiratory epithelium. The glottis consists of the true vocal cords extending to roughly 1 cm below the true cords, the paraglottic space, and the anterior and posterior commissures extending inferiorly about 1 cm. The subglottic larynx has its superior border at the inferior border of the glottis, that is, approximately 1 cm below the true vocal cords and extending inferiorly to the trachea.

Contraindications

Therapy has no "contraindications." However, a multitude of issues must be discussed in deciding which therapy is best for each patient. These issues include such things as the tumor stage, the patient's co-morbid status, prior treatments, and, of course, the patient's desires. Even in the setting of tumor recurrence and incurability, the patient should be offered palliative care.

More on Malignant Tumors of the Larynx

Overview: Malignant Tumors of the Larynx
Workup: Malignant Tumors of the Larynx
Treatment: Malignant Tumors of the Larynx
Follow-up: Malignant Tumors of the Larynx
Multimedia: Malignant Tumors of the Larynx
References

References

  1. American Joint Comittee on Cancer - Head and Neck cancer staging 2007. Available at http://www.cancerstaging.org/. Accessed August 2008.

  2. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. Jun 13 1991;324(24):1685-90. [Medline].

  3. NCCN Practice Guidelines in Oncology - v.2.2008 - Head and Neck Cancers. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/PDF/head-and-neck.pdf. Accessed 7/1/07.

  4. De Santis M, Tripodi D. [The laryngectomized patient as a psychologically maladjusted person]. Valsalva. Jun 1968;44(3):138-45. [Medline].

  5. Ah-See K. The evidence for different management strategies for laryngeal cancer: summaries of systematic reviews commissioned for an educational meeting. Clin Otolaryngol. Apr 2008;33(2):90-3. [Medline].

  6. American Cancer Society. Cancer Facts and Figures 2005. [Full Text].

  7. Audet N, Beasley NJ, MacMillan C, et al. Lymphatic vessel density, nodal metastases, and prognosis in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. Dec 2005;131(12):1065-70. [Medline].

  8. Blair A, Kazerouni N. Reactive chemicals and cancer. Cancer Causes Control. May 1997;8(3):473-90. [Medline].

  9. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. Feb 9 2006;354(6):567-78. [Medline].

  10. Cancer of the larynx. In: Myers EN, Suen JY, Myers JN, Hanna EYN. Cancer of the Head and Neck. 4th. Philadelphia: Saunders; 2003:333-378.

  11. Folz BJ, Silver CE, Rinaldo A, et al. An outline of the history of head and neck oncology. Oral Oncol. Jan 2008;44(1):2-9. [Medline].

  12. Garas J, McGuirt WF Sr. Squamous cell carcinoma of the subglottis. Am J Otolaryngol. Jan-Feb 2006;27(1):1-4. [Medline].

  13. Higgins KM, Wang JR. State of head and neck surgical oncology research--a review and critical appraisal of landmark studies. Head Neck. Dec 2008;30(12):1636-42. [Medline].

  14. Holsinger FC. Swing of the pendulum: optimizing functional outcomes in larynx cancer. Curr Oncol Rep. Mar 2008;10(2):170-5. [Medline].

  15. Kapil U, Singh P, Bahadur S, et al. Assessment of risk factors in laryngeal cancer in India: a case-control study. Asian Pac J Cancer Prev. Apr-Jun 2005;6(2):202-7. [Medline].

  16. Koufman JA, Burke AJ. The etiology and pathogenesis of laryngeal carcinoma. Otolaryngol Clin North Am. Feb 1997;30(1):1-19. [Medline].

  17. Lohynska R, Slavicek A, Bahanan A, et al. Predictors of local failure in early laryngeal cancer. Neoplasma. 2005;52(6):483-8. [Medline].

  18. Marks JE, Breaux S, Smith PG, et al. The need for elective irradiation of occult lymphatic metastases from cancers of the larynx and pyriform sinus. Head Neck Surg. Sep-Oct 1985;8(1):3-8. [Medline].

  19. McCaffrey TV, Witte M, Ferguson MT. Verrucous carcinoma of the larynx. Ann Otol Rhinol Laryngol. May 1998;107(5 Pt 1):391-5. [Medline].

  20. Mozolewski E, Maj P, Tarnowska C. [The choice of transplantation in reconstructive surgery of the larynx after partial laryngectomy]. Otolaryngol Pol. 1997;51(3):286-96. [Medline].

  21. Myers EN, Suen JY. Cancer of the larynx. Cancer of the Head and Neck. 1996;403-406.

  22. National Cancer Institute. Laryngeal Cancer (PDQ): Treatment.

  23. Nogueira CP, Dolan RW, Gooey J, et al. Inactivation of p53 and amplification of cyclin D1 correlate with clinical outcome in head and neck cancer. Laryngoscope. Mar 1998;108(3):345-50. [Medline].

  24. Oztürk O, Sari M, Inanli S, et al. Basaloid squamous cell carcinoma of the larynx: a case report. Kulak Burun Bogaz Ihtis Derg. 2005;15(5-6):125-9. [Medline].

  25. Rodriguez CP, Adelstein DJ, Rybicki LA, et al. Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapy. Head Neck. Dec 2008;30(12):1535-42. [Medline].

  26. Santos AB, Cernea CR, Inoue M, et al. Selective neck dissection for node-positive necks in patients with head and neck squamous cell carcinoma: a word of caution. Arch Otolaryngol Head Neck Surg. Jan 2006;132(1):79-81. [Medline].

  27. Sathiakumar N, Delzell E, Amoateng-Adjepong Y, et al. Epidemiologic evidence on the relationship between mists containing sulfuric acid and respiratory tract cancer. Crit Rev Toxicol. May 1997;27(3):233-51. [Medline].

  28. Scheifele C, Reichart PA, Hippler-Benscheidt M, et al. Incidence of oral, pharyngeal, and laryngeal squamous cell carcinomas among 1515 patients after liver transplantation. Oral Oncol. Aug 2005;41(7):670-6. [Medline].

  29. Shah JP, Karnell LH, Hoffman HT, et al. Patterns of care for cancer of the larynx in the United States. Arch Otolaryngol Head Neck Surg. May 1997;123(5):475-83. [Medline].

  30. Silverberg E. Cancer statistics, 1985. CA Cancer J Clin. Jan-Feb 1985;35(1):19-35. [Medline].

  31. Succo G, Bramardi F, Airoldi M, et al. Quality of life after treatment in patients with laryngeal carcinoma [in Italian]. Acta Otorhinolaryngol Ital. 1997/02;17(1):32-44.

  32. Surveillance, Epidemiology and End Results (SEER) Program. NCI; 2008. [Full Text].

  33. Uneri C, Sari M, Baglam T, et al. Effects of vitamin E on cigarette smoke induced oxidative damage in larynx and lung. Laryngoscope. Jan 2006;116(1):97-100. [Medline].

  34. Vermund H, Krajci P, Eide TJ, et al. Histopathological grading of laryngectomy specimens. APMIS. Jul-Aug 2005;113(7-8):473-88. [Medline].

  35. Vermund H, Krajci P, Eide TJ, et al. Laryngectomy whole organ serial sections--histological parameters correlated with recurrence rate. Acta Oncol. 2004;43(1):98-107. [Medline].

  36. Wenig BM. Atlas of Head and Neck Pathology. Philadelphia, Pa: WB Saunders; 1993:255.

  37. Zeitels SM, Vaughan CW, Domanowski GF. Endoscopic management of early supraglottic cancer. Ann Otol Rhinol Laryngol. Dec 1990;99(12):951-6. [Medline].

  38. Zeitels SM, Vaughan CW, Domanowski GF, et al. Laser epiglottectomy: endoscopic technique and indications. Otolaryngol Head Neck Surg. Sep 1990;103(3):337-43. [Medline].

Further Reading

Keywords

malignant tumors of the larynx, laryngeal cancer, cancer of the larynx, neck metastases, lymph node metastases, subglottic cancer, glottic cancer, supraglottic cancer, neck cancer, laryngectomy, neck tumor, subglottic tumor, glottic tumor, supraglottic tumor, transglottic tumor, tumors of the transglottic larynx, vocal cord cancer, vocal cord tumor, laryngeal malignancy, squamous cell carcinoma of the larynx,

Contributor Information and Disclosures

Author

Jonas T Johnson, MD, FACS, Chairman, Department of Otolaryngology, The Eugene N Myers, MD, Professor and Chairman of Otolaryngology, Professor, Department of Radiation Oncology, University of Pittsburgh School of Medicine; Professor, Department of Oral Maxillofacial Surgery, University of Pittsburgh School of Dental Medicine
Jonas T Johnson, MD, FACS is a member of the following medical societies: Allegheny County Medical Society, American Academy of Otolaryngology-Head and Neck Surgery, American Association for Cancer Research, American Bronchoesophagological Association, American College of Surgeons, American Head and Neck Society, American Laryngological Association, American Laryngological Rhinological and Otological Society, American Medical Association, American Radium Society, American Rhinologic Society, American Society of Clinical Oncology, Pennsylvania Medical Society, and Society of University Otolaryngologists-Head and Neck Surgeons
Disclosure: Nothing to disclose.

Coauthor(s)

Apostolos Christopoulos, MD, MSc, FRCSC, Fellow in Head and Neck Oncologic Surgery, Department of Otolaryngology, University of Pittsburgh
Disclosure: Nothing to disclose.

Emiro E Caicedo-Granados, MD, Fellow in Head and Neck Oncology/Anterior Endoscopic Skull Base Surgery, Department of Otolaryngology, University of Pittsburgh
Emiro E Caicedo-Granados, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery
Disclosure: Nothing to disclose.

Medical Editor

Jack A Coleman, MD, Consulting Staff, Franklin Surgical Associates
Jack A Coleman, MD is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American Academy of Sleep Medicine, American Bronchoesophagological Association, American College of Surgeons, American Laryngological Rhinological and Otological Society, American Society for Laser Medicine and Surgery, and Association of Military Surgeons of the US
Disclosure: Influent  None Review panel membership; accarent, inc Honoraria Speaking and teaching

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Karen Hall Calhoun, MD, William E Davis Professor and Chair, Department of Otolaryngology-Head and Neck Surgery, University of Missouri
Karen Hall Calhoun, MD is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society, American Medical Association, American Rhinologic Society, Association for Research in Otolaryngology, Society of University Otolaryngologists-Head and Neck Surgeons, Southern Medical Association, Texas Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.

CME Editor

Christopher L Slack, MD, Otolaryngology-Facial Plastic Surgery, Private Practice, Associated Coastal ENT; Medical Director, Treasure Coast Sleep Disorders
Christopher L Slack, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Arlen D Meyers, MD, MBA, Professor, Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine
Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Head and Neck Society
Disclosure: Covidien Corp Consulting fee Consulting; US Tobacco Corporation unstricted gift unknown

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.